16,976 Shares in Bruker Corporation $BRKR Purchased by Legato Capital Management LLC

Legato Capital Management LLC bought a new position in shares of Bruker Corporation (NASDAQ:BRKR) during the 4th quarter, Holdings Channel reports. The institutional investor bought 16,976 shares of the medical research company’s stock, valued at approximately $800,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Nano Cap New Millennium Growth Fund L P bought a new stake in Bruker during the fourth quarter worth about $236,000. Covestor Ltd raised its stake in Bruker by 304.6% in the fourth quarter. Covestor Ltd now owns 1,416 shares of the medical research company’s stock valued at $67,000 after buying an additional 1,066 shares during the period. PNC Financial Services Group Inc. raised its stake in Bruker by 97.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,821 shares of the medical research company’s stock valued at $274,000 after buying an additional 2,878 shares during the period. Handelsbanken Fonder AB raised its stake in Bruker by 18.1% in the fourth quarter. Handelsbanken Fonder AB now owns 34,489 shares of the medical research company’s stock valued at $1,625,000 after buying an additional 5,289 shares during the period. Finally, ProShare Advisors LLC raised its stake in Bruker by 15.6% in the fourth quarter. ProShare Advisors LLC now owns 10,482 shares of the medical research company’s stock valued at $494,000 after buying an additional 1,418 shares during the period. Institutional investors own 79.52% of the company’s stock.

Wall Street Analysts Forecast Growth

BRKR has been the topic of several research analyst reports. TD Cowen upped their price objective on Bruker from $43.00 to $45.00 and gave the company a “hold” rating in a research note on Thursday, May 7th. Citigroup upped their price objective on Bruker from $40.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Guggenheim dropped their price objective on Bruker from $58.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Jefferies Financial Group set a $50.00 price objective on Bruker in a research note on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $50.54.

Insider Buying and Selling at Bruker

In related news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the sale, the vice president owned 128,443 shares of the company’s stock, valued at $5,124,875.70. This trade represents a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 27.20% of the stock is currently owned by company insiders.

Bruker Price Performance

Bruker stock opened at $45.69 on Tuesday. The stock’s fifty day moving average price is $38.65 and its two-hundred day moving average price is $42.52. Bruker Corporation has a one year low of $28.53 and a one year high of $56.22. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. The firm has a market cap of $6.96 billion, a PE ratio of -190.38, a price-to-earnings-growth ratio of 2.74 and a beta of 1.12.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The firm had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. During the same quarter last year, the company earned $0.47 EPS. The company’s revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts expect that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 7th. Investors of record on Monday, June 22nd will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, June 22nd. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s dividend payout ratio (DPR) is -83.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.